SIROTOR, Sirolimus is also known as rapamycin, is a macrocyclic lactone antibiotic and an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections, treat lymphangioleiomyomatosis, and treat adults with perivascular epithelioid cell tumors.
SIROTOR
COMPOSITION:
Sirolimus 1 mg Tablet
MODE OF ACTION:
Sirolimus works by inhibiting T-lymphocyte activation and proliferation stimulated by antigens and cytokines such as interleukin (IL)-2, IL-4, and IL-15. In target cells, sirolimus binds to the cytoplasmic receptor FK506-binding protein-12 (FKBP12), an immunophilin, to form an immunosuppressive complex. FKBP12-sirolimus complex binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, survival, mobility, and angiogenesis.
INDICATIONS
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk. Therapeutic drug monitoring is recommended for all patients receiving Sirolimus.
DOSAGE
It is recommended that SIROTOR Tablets be used in a regimen with cyclosporine and corticosteroids. The initial dose of SIROTOR should be administered as soon as possible after transplantation. For de novo transplant recipients, a loading dose of SIROTOR of 3 times the maintenance dose should be given. A daily maintenance dose of 2 mg is recommended for use in renal transplant patients, with a loading dose of 6 mg. The initial dosage in patients ≥13 years who weigh less than 40 kg should be adjusted, based on body surface area, to 1 mg/m2/day. The loading dose should be 3 mg/m2.
STORAGE
Store at room temperature not exceeding 25ᵒC.
DISCLAIMER
This information is for the medical professionals & registered medical practitioners only. This product must be consumed with the valid prescription of registered medical practitioners.